Journal: Oncology Letters
Article Title: Role of ELP6 in tumour progression and impact on ERK1/2 signalling pathway inhibitors in skin cutaneous melanoma
doi: 10.3892/ol.2025.14996
Figure Lengend Snippet: ELP6 modulates drug sensitivity in melanoma cell lines. Box plots of the predicted clinical sensitivity of (A) AZ628, (B) Sorafenib, (C) NVP.BEZ235 and (D) VX702 in patients with SKCM categorized into ELP6 high (red) or ELP6 low (blue) groups from the The Cancer Atlas Genome database (n=468). (E) shCtrl, shELP6-2 and shELP6-3 293T cells were treated with U0126 for 0 and 48 h, and CCK-8 assays were performed to measure cell viability. shCtrl and shELP6 A375 cells were treated with U0126 for (F) 0, 24 and (G) 48 h, followed by a CCK-8 assay to assess cell viability. (H and I) shELP6-3 293T and shELP6 A375 cell lines were transfected with either the pEGFP-C2 or pEGFP- ELP6 plasmid, and treated U0126 for 48 h, followed by a CCK8 assay to evaluate cell viability. shCtrl (J) −293T and (K) -A375 cells were treated with U0126 for 24 h, ELP6 mRNA levels expression levels, normalized to GAPDH, were assessed. (L) Schematic illustrating the modulation of ERK1/2 by ELP6. Data are presented as mean ± SEM. Error bars represent the SEM and each point in the graph corresponds to an individual sample. *P<0.05; **P<0.01; ***P<0.001. ns, not significant; ELP6, elongator acetyltransferase complex subunit 6; SKCM, skin cutaneous melanoma; Ctrl, control; CCK-8, cell counting kit-8; Sh, short hairpin; SEM, standard error of the mean.
Article Snippet: The 293T, SK-MEL-2 and A375 cell lines were obtained from Procell Life Science & Technology Co., Ltd., and were authenticated using STR analysis.
Techniques: CCK-8 Assay, Transfection, Plasmid Preparation, Expressing, Control, Cell Counting